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Abstract: Viral load quantification is the amount of particular viral DNA or RNA in a blood samples. It is one of the 
surrogate biomarker of AIDS. High viral load indicates that the immune system is failed to fight against viruses. The aim of 
this study was to evaluate the impact of biofield treatment on HIV-1 and HCMV in terms of viral loads as surrogate marker. 
The viral load assay was performed on stored stock cultures of HIV infected human plasma samples before and after 7 days of 
biofield treatment using Roche COBAS
®
 AMPLICOR analyzer. Viral load (HIV-1 RNA and HCMV DNAaemia) was 
considered as surrogate marker for assessment of the impact of Mr. Trivedi’s biofield treatment in HIV infected stored plasma 
samples. The viral load quantification of HIV-1 RNA in infected stored plasma samples was significantly reduced by 65% in 
biofield treated group as compared to control. Additionally, viral load of HCMV DNAaemia in infected stored plasma samples 
was also reduced by 80% in the biofield treated group as compared to control. Because, children are more prone to HCMV 
infection and adults are generally liable to suffer from HIV-1 infection. As the biofield treatment has reduced HCMV 
DNAaemia, it could be beneficial for HIV infected children populations. Altogether, data suggest that biofield treatment has 
significantly reduced the viral load quantification in HIV-1 and HCMV infected stored plasma samples and could be a suitable 
alternative treatment strategy for AIDS patients in near future. 
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HCMV DNAaemia, AIDS, Surrogate Biomarker 
 
1. Introduction 
Human immunodeficiency virus type 1 (HIV-1) is the 
main causative agent of acquired immune deficiency 
syndrome (AIDS) [1]. HIV is a worldwide pandemic 
disease, and the number of infected peoples around the 
world increasing day by day. Recent estimate from World 
Health Organization (WHO) shows that 16.3 million people 
have died from AIDS since the beginning of the epidemic. 
Currently, around 34.3 million people alive with HIV 
infection, in which approximately 7% are young adults [2], 
infected with HIV type 1 (HIV-1) across the mucosal 
surfaces or by direct inoculation. The virus first attacks to 
dendritic cells (DCs) and subsequently spreads to cluster of 
differentiation - 4 (CD
4+
) T lymphocytes [3]. Human 
cytomegalovirus (HCMV) is a vernacular name of the 
human herpes virus - 5, a highly host-specific virus of the 
herpesviridae family rarely causes symptoms. The target 
DNA sequence is specific, located within the HCMV DNA 
polymerase gene, and is not homologous to other members 
of the human herpes virus family. The pregnant women and 
immune weakened persons are highly prone to acquire 
infection by HCMV virus. It spreads through various body 
fluids, such as blood, urine, saliva, semen, and breast milk. 
It may also causes serious morbidity and mortality in organ 
transplant recipients, immunocompromised, HIV infected 
patients and congenitally infected newborns [4]. HCMV is 
mainly prevalent in kidney transplant patients. The viral 
‘threshold load’ is very sensitive and specific for predicting 
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both white blood cell and platelet quantification in kidney 
transplant patients. The threshold value is more than 10000 
copies/mL considered as HCMV infection [5]. In infected 
adults, HIV viral load is predictive of progression to AIDS 
[6, 7] and HCMV DNAaemia predicts progression to 
disease, particularly retinitis [8]. Several study reports have 
confirmed the relation between HIV-1 viral load and 
HCMV DNAaemia levels in terms of prediction of disease 
(AIDS) progression in both adults [6, 7] and children 
[9,10]. Researchers found an excellent correlation between 
two viruses i.e. HIV infected adults are highly predictable 
for the development of HCMV end organ disease [11]. 
Hence, in this experiment the dual viruses were taken into 
consideration as a rational. Immunomodulatory therapies 
are currently used against HIV-1 infections which include 
mycophenolate mofetil, cyclosporine, interleukin-2 (IL-2), 
and various vaccines [12]. Although several treatment 
strategie are available against AIDS patients infected by 
HIV-1 such as antiretroviral agents and vaccination. But 
some difficulties are also present. Based on above lacunas, 
there is a need of an alternative way which may be useful to 
determine the viral loads by either enhancing the 
application of existing agents or by means of some 
alternative strategy or developing new drugs. Biofield 
treatment is an alternative approach which may be useful to 
improve these unfilled space associated with AIDS infected 
patients. Mr. Trivedi’s unique biofield treatment (The 
Trivedi effect
®
) has been extensively contributes in 
scientific communities in several fields [13-16]. Therefore, 
authors interested, to evaluate the impact of biofield 
treatment on viral load in HIV and HCMV infected plasma 
samples. 
2. Materials and Methods 
The viral samples (HIV-1 and HCMV) as stored stock 
cultures were procured from department of microbiology 
laboratory, P.D. Hinduja National Hospital and Medical 
Research Centre, Mumbai. The viral load assay was 
performed on HIV patients stored plasma samples before and 
after treatment using Roche COBAS AMPLICOR analyzer 
according to manufacturer’s instructions. 
2.1. Biofield Treatment Strategy and Experimental Design 
Two sets of each viral samples (HIV-1; 31 samples and 
HCMV; 5 samples) of HIV and HCMV infected stored 
plasma were used in this experiment for determination of 
viral load quantification. The first sets of both viral samples 
were considered as control. No treatment was given to these 
sets. The second sets of both viral samples were subjected to 
Mr. Mahendra Trivedi’s biofield treatment, considered as 
treated group. Both control and treated samples were 
analyzed after 7 days for viral load quantification in as per 
the standard protocols. An optimum precautionary measure 
was taken to maintain the cold chain throughout the 
experiment. The differences of viral load quantification 
before and after the treatment were noted. 
2.2. COBAS
®
 Amplicor HIV-1 Monitor Test 
The COBAS
®
 amplicor HIV-1 monitor test (v1.5) is an in 
vitro nucleic acid amplification test approved by food and 
drug administration (FDA) for the quantification of HIV-1 
RNA in human plasma on the COBAS AMPLICOR
TM
 
analyzer. This technique is a gold standard automated 
solution for testing of HIV-1 viral loads in major 
pharmaceutical trials [17]. 
2.3. COBAS
®
 Amplicor CMV Monitor Test 
The COBAS® amplicor CMV monitor test is FDA 
approved in vitro amplification test for the quantification of 
HCMV DNA in human plasma on the COBAS 
AMPLICORTM analyzer. This is an automated, sensitive, 
reliable, and specific method for quantification of 
cytomegalo viral loads in HCMV infected patients with 
high productivity (600 copies/mL to 100,000 copies/mL) 
[18].  
3. Results and Discussion 
Viral load (Fig. 1) means the amount of HIV RNA or 
HCMV DNA particles per milliliter of blood sample. Higher 
the viral titer indicates that the immune system is failed to 
fight against HIV or HCMV.  
The viral loads of HIV-1 and HCMV expressed as 
copies/ml are shown in Table 1 and 2, respectively. HIV 
RNA and HCMV DNA (viral load) and CD
4+
 T lymphocyte 
cell count are the two surrogate markers of HIV patients 
[19]. 
All the values are expressed as (IU/mL); Serial number 1-
31 denoted as viral stock human plasma samples. 
 
Figure 1. Schematic diagram related to viral load and its risk manifestation. 
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Table 1. Viral load of human immunodeficiency virus type-1 (HIV-1) in infected stored plasma samples. 
S. No. 
Viral load 
Log10 (Control) 
Viral load 
Log10 (Treatment) 
Change in Viral Load Log10 
(Treatment) - Log10 (Control) Control Treatment 
1. 91900 4.96 18500 4.27 -0.70 
2. 179000 5.25 69300 4.84 -0.41 
3. 159000 5.20 121000 5.08 -0.12 
4. 10300 4.01 4110 3.61 -0.40 
5. 107000 5.03 103000 5.01 -0.02 
6. 1650000 6.22 3320000 6.52 0.30 
7. 172000 5.24 122000 5.09 -0.15 
8. 7820 3.89 2320 3.37 -0.53 
9. 1540 3.19 3060 3.49 0.30 
10. 34400 4.52 1320 3.12 -1.40 
11. 69300 4.84 174000 5.24 0.40 
12. 2190 3.34 1760 3.25 -0.09 
13. 1860 3.27 881 2.94 -0.32 
14. 17400 4.24 8690 3.94 -0.30 
15. 216000 5.33 297000 5.47 0.14 
16. 321000 5.51 440000 5.64 0.14 
17. 17400 4.24 17400 4.24 0.00 
18. 9840 3.99 8540 3.93 -0.06 
19. 10300 4.01 3140 3.50 -0.52 
20. 99200 5.00 65700 4.82 -0.18 
21. 1650000 6.22 2900000 6.46 0.24 
22. 290000 5.46 291000 5.46 0.00 
23. 156000 5.19 401000 5.60 0.41 
24. 3070000 6.49 1450000 6.16 -0.33 
25. 587000 5.77 807000 5.91 0.14 
26. 36500 4.56 22100 4.34 -0.22 
27. 138000 5.14 68400 4.84 -0.30 
28. 6560 3.82 4230 3.63 -0.19 
29. 1900000 6.28 2580000 6.41 0.13 
30. 32800 4.52 20800 4.32 -0.20 
31. 42700 4.63 18600 4.27 -0.36 
All the values are expressed as (IU/mL); Serial number 1-31 denoted as viral stock human   plasma samples. 
Table 2. Viral loads of human cytomegalo virus (HCMV) in infected stored plasma samples. 
S. No. 
Viral load 
Log10 (Control) 
Viral load 
Log10 (Treatment) 
Change in Viral Load Log10 
(Treatment) - Log10 (Control) Control Treatment 
1. 86900 4.94 78200 4.89 -0.05 
2. 18100 4.26 8760 3.94 -0.32 
3. 40500 4.61 35000 4.54 -0.06 
4. 1570 3.20 1360 3.13 -0.06 
5. 697 2.84 <600 2.78 -0.07 
All the values are expressed as (IU/mL); Serial number 1-5 denoted as viral stock human plasma samples. 
 
Figure 2. Percentage change of viral load of A. (HIV RNA) in human immunodeficiency virus type-1 (HIV-1) and B. (HCMV DNA) in human cytomegalo virus 
(HCMV) after biofield treatment. 
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All the values are expressed as (IU/mL); Serial number 1-5 
denoted as viral stock human plasma samples 
In this experiment, vial load was considered as surrogate 
biomarker for assessment of the impact of Mr. Trivedi’s 
biofield treatment. Study was carried out in total thirty one 
infected human stored plasma samples. The result showed 
that viral load of HIV RNA in infected plasma samples were 
reduced by 65% out of thirty one samples after biofield 
treatment as compared to control. In addition, viral load were 
increased by 32% in biofield treated group and 3% 
unchanged as compared to control (Figure 2A and 3).  
 
Figure 3. Difference in viral load of HIV RNA of 31 viral stock human plasma samples after biofield treatment. VT- Viral load in treatment (IU/mL); VC- Viral 
load in control (IU/mL). 
 
Figure 4. Difference in viral load of HCMV DNA of 5 viral stock human 
plasma samples after biofield treatment. VT- Viral load in treatment 
(IU/mL); VC- Viral load in control (IU/mL). 
According to Greene et al. National Center for 
Complementary and Alternative Medicine (NCCAM), about 
2000 reported that bioelectromagnetic based therapy i.e. 
biofield is used as an effective [20], and alternative therapy 
in HIV/AIDS infected patients [21]. This study findings 
also explored in pros of biofield treatment against HIV 
infections. This study further emphasized to HCMV that are 
responsible for progression of AIDS. Viral load 
quantification of HCMV DNA were determine in total five 
infected stored plasma samples. The results showed that 
viral load of HCMV DNA in infected stored plasma 
samples were significantly reduced by 80% after biofield 
treatment as compared to control. The study outcomes 
showed a significant improvement of biofield treatment. 
Besides, the viral load of HCMV DNA were increased by 
0% and unable to detect about 20% in biofield treated group 
as compared to control (Figure 2B and 4). 
Because, 20% of HCMV DNA are inactive not in 
multiplying state but infectious. Based on existing literatures, 
HCMV load in the plasma samples of HIV infected or AIDS 
patients is an important factor in the pathogenesis of retinitis 
[22]. Another study data indicates that the risk of HCMV 
disease and death occurs in AIDS patients is directly 
proportional to the quantity of HCMV DNA (viral load) in 
plasma, and the viral load quantification is a better predictor 
than CD
4+
 T lymphocyte count [23]. The viral particles i.e. 
HIV RNA and HCMV DNA those are in multiplying state, 
possibly affected by Mr. Trivedi’s biofield treatment. The 
specific frequencies of electromagnetic radiation which 
matches with the resonance frequencies of RNA or DNA, 
probably disintegrate the respective viral RNA/DNA and 
disrupted thus reduced the viable viral titer and vice versa 
[24,25]. According to a recent report regarding biofield 
treatment which was later approved by the German 
equivalent of the FDA emphasized that cancer patients have 
experienced healing with biofield treatment. Nowadays, 
many scientists and cutting edge practitioners believed that 
the secrets of regeneration and healing lie not only on costly 
medical drugs or expensive medical treatments, but also in 
the body’s own Quantum Energy Biofield (QEB) [26]. Mr. 
Trivedi’s biofield treatment has shown to improve overall 
productivity in the field of agriculture, biotechnology, 
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material science and others field also, without utilization of 
any drugs. So, it is assumed that biofield treatment would be 
cost effective as compared to the existing treatment strategy.  
Overall, the study data indicates that biofield treatment 
significantly reduced the viral load of HIV-1 and 
simultaneously eliminate the viral load of HCMV from 
infected human plasma samples. Based on the obtained 
results, it is presumed that biofield treatment could be novel, 
cost effective and an alternative advanced strategy towards 
AIDS patients. 
4. Conclusion 
To summarize, the study results showed significant (65%) 
reduction of HIV RNA viral load from infected plasma 
samples in the biofield treated group. Experimental data also 
showed 80% elimination of HCMV DNAaemia from 
infected plasma samples after biofield treatment. It is 
assumed that Mr. Trivedi’s biofield treatment could be 
beneficial to improve the viral loads in HIV-1 infected AIDS 
patients specially children with high level of HCMV 
DNAaemia.  
Acknowledgement 
The Authors gratefully acknowledged to Trivedi Science, 
Trivedi Testimonials and Trivedi Master Wellness and P.D. 
hinduja national hospital and medical research centre, 
Mumbai, India for their support. 
 
References 
[1] Buonaguro L, Tornesello ML, Buonaguro FM (2007) Human 
immunodeficiency virus type 1 subtype distribution in the 
worldwide epidemic: Pathogenetic and therapeutic 
implications. J Virol 81: 10209-10219. 
[2] Janeway CA (2001) Immunobiology: The immune system in 
health and disease. (5thedn), New York, Garland Science. 
[3] Kassutto S, Rosenberg ES (2004) Primary HIV type 1 
infection. Clin Infect Dis 38: 1447-1453. 
[4] Chakravarti A, Kashyap B, Matlani M (2009) 
Cytomegalovirus infection: An Indian perspective. Indian J 
Med Microbiol 27: 3-11. 
[5] Eshraghi H, Hekmat R (2015) Which CMV viral load 
threshold should be defined as CMV infection in kidney 
transplant patients? Transplant Proc 47: 1136-1139. 
[6] Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, et al. 
(1996) Prognosis in HIV-1 infection predicted by the quantity 
of virus in plasma. Science 272: 1167-1170. 
[7] Obrien WA, Hartigan PM, Martin D, Esinhart J, Hill A, et al. 
(1996) Changes in plasma HIV-1 RNA and CD4+ 
lymphocyte counts and the risk of progression to AIDS. 
Veterans affairs cooperative study group on AIDS. N Engl J 
Med 334: 426-431. 
[8] Spector SA, Merrill R, Wolf D, Daukner WM (1992) 
Detection of human cytomegalovirus in plasma of AIDS 
patients during acute visceral disease by DNA amplification. J 
Clin Microbiol 30: 2359-2365. 
[9] Palumbo PE, Kwok S, Waters S, Wesley Y, Lewis D, et al. 
(1995) Viral measurement by polymerase chain reaction-based 
assays in human immunodeficiency virus-infected infants. J 
Pediatr 126: 592-595. 
[10] McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, et al. 
(1996) Age and time-related changes in extracellular viral load 
in children infected with human immunodeficiency virus. 
Pediatr Infect Dis J 15: 1087-1091. 
[11] Boriskin Y, Sharland M, Dalton R, duMont G, Booth J, et al. 
(1999) Viral loads in dual infection with HIV-1 and 
cytomegalovirus. Arch Dis Child 80: 132-136. 
[12] Lane HC (1989) The role of immunomodulators in the 
treatment of patients with AIDS. AIDS 3: S181-S185. 
[13] Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak 
G, et al. (2015) Characterization of physical, spectral and 
thermal properties of biofield treated 1,2,4-Triazole. J Mol 
Pharm Org Process Res 3: 128. 
[14] Shinde V, Sances F, Patil S, Spence A (2012) Impact of 
biofield treatment on growth and yield of lettuce and tomato. 
Aust J Basic Appl Sci 6: 100-105. 
[15] Sances F, Flora E, Patil S, Spence A, Shinde V (2013) Impact 
of biofield treatment on ginseng and organic blueberry yield. 
Agrivita J Agric Sci 35. 
[16] Nayak G, Altekar N (2015) Effect of biofield treatment on 
plant growth and adaptation. J Environ Health Sci 1: 1-9. 
[17] Berger A, Scherzed L, Sturmer M, Preiser W, Doerr HW, et al. 
(2002) Evaluation of the Cobas AmpliPrep/Cobas Amplicor 
HIV-1 Monitor Ultrasensitive Test: Comparison with the 
Cobas Amplicor HIV-1 Monitor test (manual specimen 
preparation). J Clin Virol 25: S103-S107. 
[18] Irene GS, Jennie AW, Mark JE, Carlos VP (2000) Thomas FS 
evaluation of the COBAS AMPLICOR CMV MONITOR Test 
for detection of viral DNA in specimens taken from patients 
after liver transplantation. J Clin Microbiol 38: 600-606. 
[19] Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich 
TA, Struble KA (1999) The use of plasma HIV RNA as a 
study endpoint in efficacy trials of antiretroviral drugs. AIDS. 
13: 797-804. 
[20] Ernst E (1997) Complementary AIDS therapies: The good, the 
bad and the ugly. Int J STD AIDS 8: 281-285. 
[21] Kirksey KM, Goodroad BK, Kemppainen JK, Holzemer LW, 
Bunch EH, et al. (2002) Complementary therapy use in 
persons with HIV/AIDS. J Holist Nurs 20: 264-278. 
[22] Bowen EF, Wilson P, Cope A, Sabin C, Griffiths P, et al. 
(1996) Cytomegalovirus retinitis in AIDS patients: influence 
of cytomegaloviral load on response to ganciclovir, time to 
recurrence and survival. AIDS 10: 1515-1520. 
[23] Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ (1998) 
Plasma cytomegalovirus (CMV) DNA load predicts CMV 
disease and survival in AIDS patients. J Clin Invest 101: 497-
502. 
343 Mahendra Kumar Trivedi et al.:  In vitro Evaluation of Biofield Treatment on Viral Load Against Human 
Immunodeficiency-1 and Cytomegalo Viruses 
[24] Yu ZG, Song X (2001) Variable range hopping and electrical 
conductivity along the DNA double helix. Phys Rev Lett 86: 
6018. 
[25] Tran P, Alavi B, Grunen G (2000) Charge transport along the 
lambda DNA double helix. Phys Rev Lett 85: 1564-1567. 
[26] Marshall RJ The best kept secret in nutrition: The body’s 
biofield communication system. Premier research labs. Austin, 
TX 78667. 
 
 
